Onconetix, Inc. (ONCO)
Market: NASD |
Currency: USD
Address: 201 East Fifth Street
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
📈 Onconetix, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
100-200%
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.011765 |
- |
2025-06-13 |
- |
Stock split |
|
Total Amount for 2025: $0.011765 |
| 2024 |
- |
$0.025000 |
- |
2024-09-24 |
- |
Stock split |
|
Total Amount for 2024: $0.025000 |
📅 Earnings & EPS History for Onconetix, Inc.
| Date | Reported EPS |
|---|
| 2026-06-01 (estimated upcoming) | - |
| 2025-12-08 (estimated upcoming) | - |
| 2025-08-27 (estimated upcoming) | - |
| 2025-06-12 | - |
| 2025-06-02 | - |
| 2025-05-19 | - |
| 2025-05-08 | - |
| 2024-12-10 | - |
| 2024-08-29 | - |
| 2024-08-28 | - |
| 2024-05-20 | - |
| 2024-05-19 | - |
| 2024-04-11 | - |
| 2024-04-10 | - |
📰 Related News & Research
No related articles found for "onconetix inc".
